Vaccine Design

1. Front Matter

   Pages i-xlv

   PDF

2. Immunological and Formulation Design Considerations for Subunit Vaccines

   • Mark J. Newman, Michael F. Powell

   Pages 1-42

3. Public Health Implications of Emerging Vaccine Technologies

   • Dale N. Lawrence, Karen L. Goldenthal, John W. Boslego, Donna K. F. Chandler, John R. La Montagne

   Pages 43-60

4. Preclinical Safety Assessment Considerations in Vaccine Development

   • Jeanine L. Bussiere, George C. McCormick, James D. Green

   Pages 61-79

5. Regulatory Considerations in Vaccine Design

   • Lawrence W. Davenport

   Pages 81-96

6. Clinical Considerations in Vaccine Trials with Special Reference to Candidate HIV Vaccines

   • Patricia E. Fast, Leigh A. Sawyer, Susan L. Wescott

   Pages 97-134

7. Laboratory Empiricism, Clinical Design, and Social Value

   • Donald P. Francis

   Pages 135-139

8. A Compendium of Vaccine Adjuvants and Excipients

   • Frederick R. Vogel, Michael F. Powell

   Pages 141-228

9. Adjuvant Properties of Aluminum and Calcium Compounds

   • Rajesh K. Gupta, Bradford E. Rost, Edgar Relyveld, George R. Siber

   Pages 229-248

10. Structure and Properties of Aluminum-Containing Adjuvants

    • Stanley L. Hem, Joe L. White

    Pages 249-276

11. MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines

    • Gary Ott, Gail L. Barchfeld, David Chernoff, Ramachandran Radhakrishnan, Peter van Hoogevest, Gary Van Nest

    Pages 277-296

12. Development of Vaccines Based on Formulations Containing Nonionic Block Copolymers

    • Robert N. Brey

    Pages 297-311

13. Development of an Emulsion-Based Muramyl Dipeptide Adjuvant Formulation for Vaccines

    • Deborah M. Lidgate, Noelene E. Byars

    Pages 313-324

14. Liposomal Presentation of Antigens for Human Vaccines

    • Reinhard Glück

    Pages 325-345

15. Liposome Design and Vaccine Development

    • Patricia J. Freda Pietrobon

    Pages 347-361

16. Lipid Matrix-Based Vaccines for Mucosal and Systemic Immunization

    • Raphael J. Mannino, Susan Gould-Fogerite

    Pages 363-387

17. Polymer Microspheres for Vaccine Delivery

    • Justin Hanes, Masatoshi Chiba, Robert Langer

    Pages 389-412

18. Vehicles for Oral Immunization

    • Noemi Santiago, Susan Haas, Robert A. Baughman

    Pages 413-438

19. Design and Production of Single-Immunization Vaccines Using Polylactide Polyglycolide Microsphere Systems

    • Jeffrey L. Cleland

    Pages 439-462

20. Nanoparticles as Adjuvants for Vaccines

    • Jörg Kreuter

    Pages 463-472

When my interest was first drawn to the phenomenon of vaccination for virus diseases in the late 1930s, the state of the art and the science of vaccine design was not far advanced beyond the time of Jenner at the end of the 18th century and of Pasteur a century later. In the 1930s it was still believed that for the induction of immunity to a virus-caused disease the experience of infection was required, but not for a toxin-caused disease such as diphtheria or tetanus, for which a chemically detoxified antigen was effective for immu­ nization. This prompted the question as to whether it might be possible to produce a similar effect for virus diseases using nonreplicating antigens. When in the 1930s and 1940s it was found possible to propagate influenza viruses in the chick embryo, protective effects could be induced without the need to experience infection by the use of a sufficient dose of a noninfectious influenza virus preparation. Later in the 1940s, it became possible to propagate polio and other viruses in cultures of human and monkey tissue and to immunize against other virus diseases in the same way. Later, with the advent of the era of molecular biology and genetic engineering, antigens and vaccines could be produced in new and creative ways, using either replicating or nonreplicating forms of the appropriate antigens for inducing a dose-related protective state.

• antigen
• calcium
• protein
• vaccine

`This book should be very valuable to anyone interested in the basic design of vaccine strategies or the preclinical evaluation of novel vaccines and adjuvants.'
Doody's Journal

`I have little doubt that this book will become a standard reference for future development of vaccine formulations.'
European Journal of Pharmaceutics and Biopharmaceutics

• Genentech, Inc., South San Francisco, USA

  Michael F. Powell

• Vaxcel, Inc., Norcross, USA

  Mark J. Newman

Policies and ethics